The Limited Times

Now you can see non-English news...

Corona fiasco with vaccine from Johnson & Johnson: Millions of doses unusable after a breakdown

2021-04-02T09:35:07.690Z


In order to increase the rate of vaccination, you need vaccine. But the production of the product by Johnson & Johnson now broke down.


In order to increase the rate of vaccination, you need vaccine.

But the production of the product by Johnson & Johnson now broke down.

Washington - Developing and producing vaccines is no easy feat.

But in order to defeat the coronavirus, vaccination is a crucial tool.

Four vaccines have now been approved throughout the EU: from Biontech / Pfizer, Astrazeneca - the new official name is Vaxzevria - Moderna and Johnson & Johnson.

The last manufacturer had a problem with the production of a batch.

In a production facility of a Johnson & Johnson partner company, an ingredient failed quality control and was therefore not used, the manufacturer announced on Wednesday (local time).

The company did not disclose how many doses of vaccine were affected by the problem at contract manufacturer Emergent Biosolutions.

According to a report in the

New York Times

, up to 15 million doses of the vaccine are believed to be unusable.

Workers at a Baltimore, Maryland, facility allegedly accidentally mixed up the ingredients.

Federal officials would attribute the error to "human error," the report said.

+

Johnson & Johnson corona vaccine vials are in the National Jewish Hospital pharmacy for distribution in east Denver.

© David Zalubowski / dpa

Problem with the production of the vaccine by Johnson & Johnson - additional expertise is to come

Johnson & Johnson said it plans to continue delivering 100 million cans to the US government by the end of May, as previously promised.

The company will now provide the contract manufacturer Emergent Biosolutions with additional expertise and monitor production in the US state of Maryland on site, it said.

"Quality and safety are still our top priority," said the company.

The manufacturing facility of Emergent Biosolutions has not yet been approved by the US Food and Drug Administration (FDA) for the vaccine.

However, the company is already preparing production in order to be able to meet delivery targets.

According to the newspaper, an investigation by the FDA can be expected, which could further restrict production.

Despite the incident, more than a billion vaccine doses are expected to be produced by the end of the year.

The great advantage of the vaccine from Johnson & Johnson: The vaccine unfolds its full effect after just one injection.

To put it into perspective: Astrazeneca wants to deliver up to 15 million cans to Germany from April to June, Biontech / Pfizer 40, Moderna 6.4 and Johnson & Johnson 10 million.

(dpa / AFP / cibo)

List of rubric lists: © David Zalubowski / dpa

Source: merkur

All news articles on 2021-04-02

You may like

Trends 24h

News/Politics 2024-03-28T06:04:53.137Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.